中文傳媒(600373.SH):擬與控股子公司共同投設基金管理人
格隆匯8月12日丨中文傳媒(600373.SH)公佈,公司擬與控股子公司北京智明星通科技股份有限公司(“智明星通”)及人和謙臨(天津)管理諮詢合夥企業(有限合夥)(“人和謙臨”)共同出資設立基金管理人,註冊資本人民幣1000萬元。
公司以自有資金出資190萬元,佔比19%,智明星通以自有資金出資510萬元,佔比51%,人和謙臨以自有資金出資300萬元,佔比30%。
通過共同設立基金管理人,能夠更好地發揮智明星通在互聯網及遊戲行業的資源、資金優勢,建立優質的內部孵化平台,有利於進一步完善自身投資業務版塊,增強公司投資能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.